Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and zanidatamab in HER2-positive advanced gastric cancer
NCT05270889Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab, tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Yonsei University. Status: unknown.
02
Drugs
zanidatamabtislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05270889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270889.